Akero Therapeutics Inc.

23.73-0.3900-1.62%Vol 96.14K1Y Perf -26.19%
Sep 24th, 2021 16:00 DELAYED
BID23.73 ASK23.79
Open24.00 Previous Close24.12
Pre-Market- After-Market-
 - -  - -%
Target Price
53.14 
Analyst Rating
Strong Buy 1.00
Potential %
123.94 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
35.27 
Earnings Rating
Market Cap827.28M 
Earnings Date
11th Nov 2021
Alpha0.01 Standard Deviation0.15
Beta0.52 

Today's Price Range

23.1924.14

52W Range

17.6634.87

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-4.66%
1 Month
7.04%
3 Months
-14.15%
6 Months
-19.61%
1 Year
-26.19%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AKRO23.73-0.3900-1.62
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.72-0.83-15.28
Q01 2021-1.01-0.4357.43
Q04 2020-0.72-0.86-19.44
Q03 2020-0.48-0.63-31.25
Q02 2020-0.48-0.57-18.75
Q01 2020-0.60-0.4230.00
Q04 2019-0.59-0.556.78
Q03 2019-0.43-0.56-30.23
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Nov 2021
Estimated EPS Next Report-0.91
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume96.14K
Shares Outstanding34.86M
Shares Float22.02M
Trades Count1.89K
Dollar Volume6.91M
Avg. Volume248.61K
Avg. Weekly Volume82.59K
Avg. Monthly Volume152.89K
Avg. Quarterly Volume222.42K

Akero Therapeutics Inc. (NASDAQ: AKRO) stock closed at 23.73 per share at the end of the most recent trading day (a -1.62% change compared to the prior day closing price) with a volume of 96.14K shares and market capitalization of 827.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Akero Therapeutics Inc. CEO is Andrew Cheng.

The one-year performance of Akero Therapeutics Inc. stock is -26.19%, while year-to-date (YTD) performance is -8.02%. AKRO stock has a five-year performance of %. Its 52-week range is between 17.66 and 34.87, which gives AKRO stock a 52-week price range ratio of 35.27%

Akero Therapeutics Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 3.94, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -53.09%, a ROC of -58.17% and a ROE of -57.74%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Akero Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.91 for the next earnings report. Akero Therapeutics Inc.’s next earnings report date is 11th Nov 2021.

The consensus rating of Wall Street analysts for Akero Therapeutics Inc. is Strong Buy (1), with a target price of $53.14, which is +123.94% compared to the current price. The earnings rating for Akero Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akero Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akero Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.34, ATR14 : 1.12, CCI20 : -46.72, Chaikin Money Flow : 0.05, MACD : 0.41, Money Flow Index : 73.41, ROC : -1.04, RSI : 51.85, STOCH (14,3) : 24.92, STOCH RSI : 0.22, UO : 48.95, Williams %R : -75.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akero Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

CEO: Andrew Cheng

Telephone: +1 650 487-6488

Address: 170 Harbor Way, South San Francisco 94080, CA, US

Number of employees: 17

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

63%38%

Bearish Bullish

63%37%

News

Stocktwits